Who are Rifamycin SV MMX's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RIF, clarithromycin, rifabutin, Rifampicin (RIF), Rifampicin Capsules, Rifampicin alone, Rifampicin (R).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rifamycin-sv-mmx.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Rifamycin SV MMX — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rifamycin SV MMX (Rifamycin SV MMX) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ansamycin antibiotic. Area: Gastroenterology / Infectious Disease.

phase 3 Ansamycin antibiotic Bacterial RNA polymerase Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Rifamycin SV MMX (Rifamycin SV MMX) — RedHill Biopharma Limited. Rifamycin SV MMX is a modified-release antibiotic that targets bacterial RNA polymerase to inhibit bacterial protein synthesis, with enhanced delivery to the colon.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rifamycin SV MMX TARGET	Rifamycin SV MMX	RedHill Biopharma Limited	phase 3	Ansamycin antibiotic	Bacterial RNA polymerase
RIF	RIF	South China Children's Leukemia Group	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
clarithromycin, rifabutin	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)
Rifampicin (RIF)	Rifampicin (RIF)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Rifamycin antibiotic	Bacterial RNA polymerase (RNAP)
Rifampicin Capsules	Rifampicin Capsules	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Rifampicin alone	Rifampicin alone	Miguel Santín	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifampicin (R)	Rifampicin (R)	University College, London	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ansamycin antibiotic class)

RedHill Biopharma Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rifamycin SV MMX — Competitive Intelligence Brief. https://druglandscape.com/ci/rifamycin-sv-mmx. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab